机构:[1]State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology andHepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,China[2]Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital,Sichuan University and Collaborative Innovation Center, Chengdu, China四川大学华西医院[3]Department of Dermatology, University of Texas Southwestern Medical Center,Dallas, TX, USA[4]Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai, China[5]Department of Gastroenterology,Changsha Central Hospital, Changsha, China[6]Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China[7]Urology Department, The First Affiliated Hospital of Zhejiang University, Zhejiang, China浙江大学医学院附属第一医院[8]Department of Bioinformatics & Systems Biology, KeyLaboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology,Wuhan, China
Checkpoint blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 promotes T-cell-mediated immunosurveillance against tumours, and has been associated with marked clinical benefit in cancer patients. Antibodies against PD-L1 function by blocking PD-L1 on the cell surface, but intracellular storage of PD-L1 and its active redistribution to the cell membrane can minimize the therapeutic benefits, which highlights the importance of targeting PD-L1 throughout the whole cell. Here, we show that PD-L1 is palmitoylated in its cytoplasmic domain, and that this lipid modification stabilizes PD-L1 by blocking its ubiquitination, consequently suppressing PD-L1 degradation by lysosomes. We identified palmitoyltransferase ZDHHC3 (DHHC3) as the main acetyltransferase required for the palmitoylation of PD-L1, and show that the inhibition of PD-L1 palmitoylation via 2-bromopalmitate, or the silencing of DHHC3, activates antitumour immunity in vitro and in mice bearing MC38 tumour cells. We also designed a competitive inhibitor of PD-L1 palmitoylation that decreases PD-L1 expression in tumour cells to enhance T-cell immunity against the tumours. These findings suggest new strategies for overcoming PD-L1-mediated immune evasion in cancer.
基金:
National Key Research and Development Plan [2016YFC0906000, 2016YFC0906003, 2016YFC0906002, 2017YFC0906600]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81572326, 81322036, 81421001, 81773752, 81702969, 81874050, 21335002, 31671360]; Key Program of the Science and Technology Bureau of Sichuan [2017SZ00005]; Top-Notch Young Talents Program of China [ZTZ2015-48]; 'Tang Scholar' programme [JX-2017]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20152514]; 'ShuGuang' project - Shanghai Municipal Education CommissionChinese Academy of Sciences; Shanghai Education Development Foundation [15SG16]; National Key Technology Support ProgramNational Key Technology R&D Program [2015BAI13B07]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [18ZR1402800]
第一作者机构:[1]State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology andHepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai,China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Yao Han,Lan Jiang,Li Chushu,et al.Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours[J].Nature biomedical engineering.2019,3(4):306-317.doi:10.1038/s41551-019-0375-6.